FDA Grants Fast Track Designation to PWS Potential Therapy LV-101
The U.S. Food and Drug Administration (FDA) has granted fast track designation to LV-101 (intranasal carbetocin), a treatment candidate for people with Prader-Willi syndrome (PWS). This designation is granted to promising therapies intended to treat serious diseases with unmet medical needs. It aims to quicken treatment development by…